web analytics
1.8 C
Munich
Friday, December 2, 2022

Todays Equity Focus is Medical Marijuana Inc (OTCMKTS:MJNA)

Medical Marijuana Inc (OTCMKTS:MJNA) continues to see higher highs and higher lows since moving up off $0.0275 lows in recent months. The stock remains an Investors favorite and a staple among the top most traded stocks on the entire exchange.

When pot stocks heat up MJNA is a great place to be with its history of parabolic moves; catalysts suggesting another pot boom is here include Canada’s new prime minister promising legalization immediately, DEA being told by California judge to stop interfering with dispensaries, billionaire Richard Branson suggesting a decriminalization amendment in the U.N, 6,000 non-violent drug offenders released Nov 1st, Australia lifting ban on medical MJ, New York opening medical MJ dispensaries in January, Colorado revenues increasing and more.

Medical Marijuana Inc (OTCMKTS:MJNA) mission is to be the premier cannabis and hemp industry innovators, leveraging our team of professionals to source, evaluate and purchase value-added companies and products, while allowing them to keep their integrity and entrepreneurial spirit. They strive to create awareness within our industry, develop environmentally-friendly, economically sustainable businesses, while increasing shareholder value.

MJNA most profitable division is HempMeds, an exclusive master distributor for MJNA that provides cannabidiol (CBD) products made from industrial hemp that are already available in all 50 states and more than 40 countries. The unit boasts fast growing revenues and reported $2,876,438 in sales in Q3.

MJNA says their HempMeds™ sales operation has been greatly streamlined and they have cut back on inefficient expenses. The world is waking up to the vast untapped potential of cannabinoid-rich hemp oil and our flagship product, Real Scientific Hemp Oil™ (RSHO™), continues to show increasing demand. Combining our reduced manufacturing costs with improving demand from lower retail prices – we expect to see improving gross margins as the year progresses. Over the course of the last year we have been able to decrease our retail sales price by over 30% while still increasing margins and overall volume.”

Several Months ago Project CBD, a California educational nonprofit that focuses on cannabis science and therapeutics published an article called HEMP OIL HUSTLERS; Medical Marijuana Inc., HempMeds & Kannaway that has raised a stir especially with MJNA management who filed a $100 million lawsuit. As per the recent shareholder letter ”To date, two parties have settled in our litigation.”

To Find out the inside Scoop on MJNA Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

In September MJNA announced it has signed a U.S. manufacturer for sourcing of its Gold Label cannabidiol (CBD) hemp oil brand Real Scientific Hemp Oil™ (RSHO™). The sourcing agreement is for a minimum of $2,500,000 USD for a 12-month period. The first two months of the contract have already been sold, shipped and processed.

In February MJNA announced HempMeds(R) Mexico is the marketing and distribution company for the first cannabidiol (CBD) product granted permission by the Mexican government for import. The country’s health administration issued the first two import permits. The company will begin shipping RSHO-XTM to Mexico on Feb. 8, 2016.

On May 17 MJNA announced its hemp biotech investment, AXIM Biotechnologies, Inc. has begun the world’s first human dermatological clinical trials on psoriasis (PsO) and atopic dermatitis (AD) commonly known as eczema based on AXIM’s AX-1602 proprietary, patent-pending topical ointment formulation containing cannabigerol (CBG) and other cannabinoids. Conducting the clinical trials is a world-renowned dermatologist and specialist on psoriasis and atopic dermatitis, Dr. Marcus Meinardi, at The Maurits Clinics in The Hague, The Netherlands. Psoriasis and eczema are estimated to affect nearly 200 million people worldwide by 2024 with combined market estimates at $16 billion by 2022.

Cannabigerol (CBG) “The Stem Cell Cannabinoid” A non-psychoactive cannabinoid found in the plant genus Cannabis, CBG has a broad range of biological efficacies. Found to act as a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist, CBG has also been found to have an anti-nausea and anti-emetic (anti-vomiting) effects. In addition, CBG has demonstrated an anti-inflammatory effect, has been shown to reduce pain, ease symptoms of psoriasis, act as an antibacterial agent and even slow the proliferation of tumor cells in vitro and in-vivo.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $137 million market valuation MJNA has a long history of losses that has resulted in a massive debt problem that has caused and will continue to cause significant dilution. But MJNA is one pot stock to watch when the sector heats up; they are masters at selling the sizzle on the pot sector as well as getting themselves featured by mainstream media, in the past this has resulted in spectacular short term moves. We will be updating on MJNA when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with MJNA.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in MJNA either long or short and we have not been compensated for this article.

More articles

1 COMMENT

  1. Why doesn’t this article, written the day after MJNA filed its 1Q/16 results on May 23, 2016, report that MJNA generated only $1.5M of revenue in 1Q/16 and had a net loss of $9.7M?

    The vaunted HempMeds saw only $1.2M of revenue in 1Q/16, with YoY revenues down 44% from 1Q/15 and also down 15% sequentially from 4Q/15.

    Why is this “report” still talking about financials from 3Q/15?

    Why doesn’t this report mention that MJNA has been running up the share count via ongoing note conversions, and now has nearly 2.9B outstanding shares?

    Project CBD’s article was written more than a year ago (Oct, 2014), not “several months ago” and the case has yet to enter the trial phase. In fact, the case is on hold pending appeal in 4th District Appelate Court in CA of the finding in civil court that MJNA has the right to sue Project CBD.

    Was any actual research done on this so-called article, or is it just a reiteration of older pieces with a little news on AXIM added (BTW, Axim lost $954K on revenues of $14K in 1Q/16)

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.